Unknown

Dataset Information

0

Discovery of ONO-7300243 from a Novel Class of Lysophosphatidic Acid Receptor 1 Antagonists: From Hit to Lead.

ABSTRACT: Lysophosphatidic acid (LPA) evokes various physiological responses through a series of G protein-coupled receptors known as LPA1-6. A high throughput screen against LPA1 gave compound 7a as a hit. The subsequent optimization of 7a led to ONO-7300243 (17a) as a novel, potent LPA1 antagonist, which showed good efficacy in vivo. The oral dosing of 17a at 30 mg/kg led to reduced intraurethral pressure in rats. Notably, this compound was equal in potency to the ?1 adrenoceptor antagonist tamsulosin, which is used in clinical practice to treat dysuria with benign prostatic hyperplasia (BPH). In contrast to tamsulosin, compound 17a had no impact on the mean blood pressure at this dose. These results suggest that LPA1 antagonists could be used to treat BPH without affecting the blood pressure. Herein, we report the hit-to-lead optimization of a unique series of LPA1 antagonists and their in vivo efficacy.

SUBMITTER: Terakado M 

PROVIDER: S-EPMC5066152 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Discovery of ONO-7300243 from a Novel Class of Lysophosphatidic Acid Receptor 1 Antagonists: From Hit to Lead.

Terakado Masahiko M   Suzuki Hidehiro H   Hashimura Kazuya K   Tanaka Motoyuki M   Ueda Hideyuki H   Kohno Hiroshi H   Fujimoto Taku T   Saga Hiroshi H   Nakade Shinji S   Habashita Hiromu H   Takaoka Yoshikazu Y   Seko Takuya T  

ACS medicinal chemistry letters 20160819 10

Lysophosphatidic acid (LPA) evokes various physiological responses through a series of G protein-coupled receptors known as LPA<sub>1-6</sub>. A high throughput screen against LPA<sub>1</sub> gave compound <b>7a</b> as a hit. The subsequent optimization of <b>7a</b> led to <b>ONO-7300243</b> (<b>17a</b>) as a novel, potent LPA<sub>1</sub> antagonist, which showed good efficacy <i>in vivo</i>. The oral dosing of <b>17a</b> at 30 mg/kg led to reduced intraurethral pressure in rats. Notably, this c  ...[more]

Similar Datasets

Unknown Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials.
| S-EPMC8306951 | biostudies-literature
Unknown 2-Carba-lysophosphatidic acid is a novel β-lysophosphatidic acid analogue with high potential for lysophosphatidic acid receptor activation and autotaxin inhibition.
| S-EPMC8405639 | biostudies-literature
Unknown Discovery of 3-Substituted 1H-Indole-2-carboxylic Acid Derivatives as a Novel Class of CysLT1 Selective Antagonists.
| S-EPMC4789669 | biostudies-literature
Unknown Aiming drug discovery at lysophosphatidic acid targets.
| S-EPMC2989581 | biostudies-literature
Unknown Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A2B Adenosine Receptor Antagonists.
| S-EPMC4027370 | biostudies-literature
Unknown Discovery of novel GPVI receptor antagonists by structure-based repurposing.
| S-EPMC4074120 | biostudies-literature
Unknown Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening.
| S-EPMC3711565 | biostudies-literature
Unknown Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6.
| S-EPMC2719412 | biostudies-literature
Unknown Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists.
| S-EPMC4315423 | biostudies-literature
Unknown Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists.
| S-EPMC4025839 | biostudies-other